Preventative Health OS.
A unified platform combining testing, interpretation, protocols, and family cascade into the operating system for preventative health practitioners.
of chronic disease is preventable. Almost none of it is being prevented.
Healthcare systems spend trillions treating conditions that could be caught earlier. Prevention stays theoretical because practitioners lack a single platform connecting genetics, biomarkers, and action.
DNA test here. Blood panel there. Results arrive as PDFs, not protocols. Nothing connects to action.
Multi-omic data requires specialist interpretation. No single platform integrates all three into an actionable plan.
Testing companies stop at the report. No protocol, no adherence tracking, no retesting cycle. Insight without action is entertainment.
Functional medicine practitioners are scarce and expensive. Prevention needs a platform that augments them, not replaces them.
Four modules. One data engine.
Practitioners order multi-modal testing (DNA, epigenetics, blood panels). Results return interpreted through the GENO Engine into actionable risk profiles. Consumers see a biological dashboard with longitudinal tracking.
Identify hereditary risk patterns, map the family tree, automate GDPR/HIPAA-compliant outreach to at-risk relatives. One patient becomes 3–5. The consumer becomes the distribution channel.
Practitioners build personalised protocols. Platform tracks adherence, retesting, and outcomes over time. Protocol template marketplace. Full client lifecycle: intake, profiles, scheduling, outcome logging.
Aggregated anonymised outcome data. Every completed protocol-to-retest cycle generates structured data. Anonymous benchmarking across practitioners. Platform measurably better at 1,000 users than at 100.
Four forces. One window.
Genomics England and UK Biobank have normalised large-scale genomic data. Multi-omic testing costs dropped 90% in five years. A £100 epigenetics test is now commercially viable. The infrastructure exists.
LLM-class models can now synthesize multi-omic data into actionable protocols at scale. The PhD-per-patient interpretation barrier is gone. The missing layer is the structured data engine to feed it.
NHS Long Term Plan explicitly targets prevention ROI. Integrated Care Systems under record budget pressure. Prevention is now a commissioning priority, not a nice-to-have. The institutional buyer is ready.
Post-COVID health consciousness plus the GLP-1 and longevity wave has shifted consumer appetite from reactive to proactive. Demand for personalised health optimisation is at an all-time high.
A £51B problem. No full-stack player.
The preventative health market sits at the intersection of diagnostics, digital health, and clinical workflow. No single platform currently owns it end-to-end.
Every practitioner is currently stitching together 4–6 disconnected tools to run a prevention programme. GENO replaces that entire stack with one platform and adds the data layer none of them have.
At 10,000 completed protocols, GENO holds the world’s largest structured preventative outcome dataset. That dataset is licensable to pharma, insurers, and research. A revenue stream no pure SaaS competitor can replicate.
The functional medicine practitioner model is identical in the US, EU, and Australia. UK launch validates the clinical model. International expansion is a distribution play, not a product rebuild.
Pay because your health is measurably improving.
Visible improvement at every retest drives organic subscription retention. Without outcomes tracking proving the protocol works, there is no reason to retest. This loop drives subscription revenue and generates longitudinal data.
One patient becomes 3–5. When hereditary risk is flagged, the consumer invites family directly. Trust-based distribution converts at >40% vs industry baseline ~30%. No ad spend required.
Outcomes data refines interpretation, which improves protocols, which attracts more practitioners, which generates more data. No single competitor can replicate the full loop without starting from scratch.
Already in motion. Not a concept.
Three-sided revenue from one data engine.
- SaaS subscription for workflow tools
- Tiered pricing based on patient volume
- Entry tier priced to maximise practitioner count (data compounds)
- Premium tier: marketplace access & benchmarking
- Per-test fees (~£552 blended entry)
- Health management subscription
- Own-brand supplement purchases
- Retest revenue (90-day cycles)
- Population health data & outcomes reporting
- “We can prove biological age decreased by X over 12 months”
- Anonymised prescribing data licensable to pharma
- Unlocks at 12–18 months post-launch
£552 entry. 55% contribution margin.
Per-consumer unit economics for the standard entry tier.
LTV compounds with subscriptions
£2.4K
Entry £552 + subscriptions £720 + supplements £1,200 + retesting. The cascade multiplier (1→3–5) means effective CAC drops to £0 for family referrals. Margins improve 15–25% at volume.
No one occupies the full quadrant.
Defensibility: 2/8 → 5.7/8
Why us.
The team that can execute this must combine clinical credibility, data architecture, and commercial distribution.
[Role, background, relevant expertise. Why this person can build and sell this product.]
[Role, background, technical credentials. Why this person can architect the data engine.]
[Clinical credentials, practitioner network, relevant publications or regulatory experience.]
Raising £500K. Pre-seed. £5M post-money.
Milestones this raise funds
- 30–50 practitioners onboarded on Module 1 (Test & Interpret)
- 200+ consumers with structured 30/60/90-day outcome data
- Family cascade demonstrated: 1 patient producing 2–3+ referrals
- Revenue trajectory: £30K–50K/month run rate by month 12
- At least one strategic partnership formalised (Vitality or equivalent)
Hitting these numbers supports a seed raise at £3–5M on a £15–20M valuation. Payer revenue and Modules 2 & 3 are seed territory.